SCHEMBL10073693

SCHEMBL10073693

O=C(Cn1nc(N2CCNCC2)ccc1=O)N1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 6/20 0.45
▸ HTR2A P28223 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ TP53 P04637 3/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ MITF O75030 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ KDM4E B2RXH2 4/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ POLB P06746 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13533076 0.80 HTR2C (0.54) HTR2CHTR2A
SCHEMBL10074092 0.77 MEN1 (0.58) TSHRTP53KDM4EHSD17B10ALDH1A1
SCHEMBL10073890 0.77 HTR2C (0.53) HTR2CHTR2ATP53
SCHEMBL23432738 0.71 TP53 (0.60) TP53HSD17B10POLBALDH1A1SMN1; SMN2
SCHEMBL10074091 0.70 HTR2C (0.54) HTR2CHTR2ATP53
SCHEMBL23432349 0.70 TP53 (0.58) TP53HSD17B10POLBSMN1; SMN2USP2
SCHEMBL2073211 0.68 HSD17B10 (0.69) TSHRTP53NPC1LMNARAB9A
SCHEMBL255444 0.68 HSD17B10 (0.69) TSHRTP53NPC1LMNARAB9A
SCHEMBL13533715 0.68 HTR2C (0.52) HTR2CHTR2ATP53
SCHEMBL27319478 0.68 ALDH1A1 (0.82) LMNAHTTKDM4EHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2310395-B1 9-SUBSTITUTED-B-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS VETOQUINOL SA (FR) 2012-01-18 — — EP disclosed
US-8071590-B2 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials VETOQUINOL SA (FR) 2011-12-06 — — US disclosed
WO-2010004394-A1 9-SUBSTITUTED-B-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS VETOQUINOL SA (FR) 2010-01-14 — — WO disclosed
US-20100009980-A1 NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS VETOQUINOL SA (FR) 2010-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009980-A1 NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS Q6ZSR9, NQO2, RECQL HTR2C 3559/4885HTR2A 4321/4885TSHR 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback